As of Wednesday, December 17, Werewolf Therapeutics, Inc.’s HOWL share price has surged by 8.80%, which has investors questioning if this is right time to sell.

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Fintel reports that on December 19, 2025, HC Wainwright & Co. maintained coverage of Werewolf Therapeutics (NasdaqGS:HOWL) ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to ...

Matthew Galea is a features writer for CBR. He spends his day as a high school English teacher, and every other minute watching, thinking and writing about movies and television. From Lon Chaney Jr.'s ...